ArticleCureus2026
Multifocal Breast Cancer With Discordant Molecular Profiles in a Patient With NF1 and MUTYH Germline Variants: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synchronous Multicentric Breast Cancer With Opposite Molecular Phenotypes: A Case Report and Therapeutic Considerations.Case reports in oncological medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The identification of synchronous breast cancers with inter-tumor heterogeneity presents significant diagnostic and therapeutic challenges, particularly in cases of discordant biomarker profiles. We report the case of a 66-year-old African American female with a significant family history of cancer, including two sisters diagnosed with breast cancer at ages 29 and 32. Diagnostic imaging revealed two synchronous right breast masses with similar high-grade histomorphology but discordant molecular profiles, with the larger focus being hormone receptor-negative and human epidermal growth factor receptor 2 (HER2)-positive, and the smaller focus being triple-negative. Initial germline testing identified a heterozygous variant of uncertain significance (VUS) in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.